Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab combined with EGF816 or INC280 for biomarker-selected advanced non-small cell lung cancer
NL-OMON44688Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, nazartinib and capmatinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: 6-month progression-free survival rate. Started May 2015; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON44688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44688.